ARTICLE | Clinical News
APT070: Phase IIa
March 3, 2003 8:00 AM UTC
Adprotech started a dose-escalating, double-blind, placebo-controlled, U.K. Phase IIa study in 45 transplant patients. APT070 also is in Phase II testing for rheumatoid arthritis. ...